223 related articles for article (PubMed ID: 25999488)
1. The drug push.
Servick K
Science; 2015 May; 348(6237):850-3. PubMed ID: 25999488
[No Abstract] [Full Text] [Related]
2. A new antibiotic and the evolution of resistance.
Arias CA; Murray BE
N Engl J Med; 2015 Mar; 372(12):1168-70. PubMed ID: 25785976
[No Abstract] [Full Text] [Related]
3. Fix the antibiotics pipeline.
Cooper MA; Shlaes D
Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
[No Abstract] [Full Text] [Related]
4. Drug development: Time for teamwork.
May M
Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
[No Abstract] [Full Text] [Related]
5. Report urges controversial 'delinkage' to foster new antibiotics.
Holmes D
Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
[No Abstract] [Full Text] [Related]
6. Bank tests drug development waters.
Mullard A
Nat Rev Drug Discov; 2014 Sep; 13(9):643-4. PubMed ID: 25176422
[No Abstract] [Full Text] [Related]
7. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
8. Antibacterial R&D incentives.
Laxminarayan R; Powers JH
Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
[No Abstract] [Full Text] [Related]
9. Overcoming the current deadlock in antibiotic research.
Schäberle TF; Hack IM
Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
[TBL] [Abstract][Full Text] [Related]
10. The drug-resistant bacteria that pose the greatest health threats.
Willyard C
Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
[No Abstract] [Full Text] [Related]
11. Oleamycins A and B: new antibacterial cyclic hexadepsipeptides isolated from a terrestrial Streptomyces sp.
Raju R; Gromyko O; Andriy B; Fedorenko V; Luzhetskyy A; Müller R
J Antibiot (Tokyo); 2014 Apr; 67(4):339-43. PubMed ID: 24448627
[No Abstract] [Full Text] [Related]
12. David Haslam. Interview by Asher Mullard.
Haslam D
Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
[No Abstract] [Full Text] [Related]
13. A three-step plan for antibiotics.
Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
[No Abstract] [Full Text] [Related]
14. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
Simpkin VL; Renwick MJ; Kelly R; Mossialos E
J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
[TBL] [Abstract][Full Text] [Related]
15. Incentives aim to boost antibiotic development.
Roberts JP
Nat Biotechnol; 2012 Aug; 30(8):735. PubMed ID: 22871701
[No Abstract] [Full Text] [Related]
16. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
Spellberg B; Sharma P; Rex JH
Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
[No Abstract] [Full Text] [Related]
17. MBJ-0086 and MBJ-0087, new bicyclic depsipeptides, from Sphaerisporangium sp. 33226.
Kawahara T; Itoh M; Izumikawa M; Hashimoto J; Sakata N; Tsuchida T; Shin-ya K
J Antibiot (Tokyo); 2015 Jan; 68(1):67-70. PubMed ID: 25095808
[No Abstract] [Full Text] [Related]
18. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
19. In the midst of the antimicrobial discovery conundrum: an overview.
Tomaras AP; Dunman PM
Curr Opin Microbiol; 2015 Oct; 27():103-7. PubMed ID: 26356257
[No Abstract] [Full Text] [Related]
20. The $2.6 billion pill--methodologic and policy considerations.
Avorn J
N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
